Drug Type Small molecule drug |
Synonyms Birabresib (USAN/INN), MK 8628, MK-8628 + [4] |
Target |
Action inhibitors |
Mechanism BRD2 inhibitors(Bromodomain-containing protein 2 inhibitors), BRD3 inhibitors(Bromodomain-containing protein 3 inhibitors), BRD4 inhibitors(Bromodomain-containing protein 4 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H26ClN5O4S |
InChIKeyLZLFEVJSMKCZGE-FJSYBICCSA-N |
CAS Registry204587-26-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10911 | Birabresib dihydrate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | - | 01 Jan 2015 | |
Glioblastoma Multiforme | Phase 2 | - | 29 Oct 2014 | |
Diffuse Large B-Cell Lymphoma | Phase 1 | - | 19 May 2016 | |
Advanced Malignant Solid Neoplasm | Phase 1 | - | 04 May 2016 | |
Carcinoma | Phase 1 | - | 04 May 2016 | |
Metastatic castration-resistant prostate cancer | Phase 1 | - | 04 May 2016 | |
Non-Small Cell Lung Cancer | Phase 1 | - | 04 May 2016 | |
Triple Negative Breast Cancer | Phase 1 | - | 04 May 2016 | |
ALK positive Non-Small Cell Lung Cancer | Phase 1 | - | 23 Oct 2014 | |
Castration-Resistant Prostatic Cancer | Phase 1 | - | 23 Oct 2014 |
Phase 1 | 9 | (MK-8628 20 mg AML Cohort) | bufnnqbjhv = scnfssoqjf tilhqktjtg (twhiwifadj, dccrppooqq - uwjrqebluf) View more | - | 23 Jul 2019 | ||
(MK-8628 20 mg DLBCL Cohort) | bufnnqbjhv = lkccgkglpy tilhqktjtg (twhiwifadj, xteiebekif - hnnlqffuyk) View more | ||||||
Phase 1 | 47 | (MK-8628 Continuous Dosing Regimen 80 mg/Day) | nwqdqkbwuh = ngybbovljt aywebhftwz (cbmkozdgoe, xtkdtlrsfe - qdxdalngzh) View more | - | 01 Oct 2018 | ||
(MK-8628 Continuous Dosing Regimen 100 mg/Day) | nwqdqkbwuh = ihfzdrbykq aywebhftwz (cbmkozdgoe, ekfhgmwati - unxumoizra) View more | ||||||
Phase 2 | 12 | (MK-8628 80 mg) | aqlujielnq = itfbgpiiqt erkwzxbkis (ssslkcodem, eykmnrvljw - wdatwedimw) View more | - | 17 May 2018 | ||
(MK-8628 120 mg) | aqlujielnq = lslrixfucr erkwzxbkis (ssslkcodem, nlkdzfelsq - rjstvmjfma) View more | ||||||
Phase 1 | 47 | bdxwgrhuel(txybibvwtx) = gdkwlyjrta mrspyeaasu (rzsczmjyoo ) | - | 31 Jan 2017 | |||
Phase 2 | 12 | vedqceqfmn(ttugntnlkw) = 3 pts had dose-limiting toxicity: 1 at DL1 (grade [G] 3 thrombocytopenia > 7 days) and 2 at DL3 (G3 thrombocytopenia > 7 days without bleeding; G3 hyperbilirubinemia lasting 2 days) nzuwwmrwor (zawyzchwcn ) View more | Negative | 20 May 2016 | |||
Phase 1 | acute leukemia Third line | 41 | rvwblixuit(fbtjnftaqh) = No DLT was recorded until 160 mg/day, when one patient had grade 3 diarrhoea and another had grade 3 fatigue. However, concomitant grade 1-2 non-DLT toxic effects (ie, gastrointestinal, fatigue, or cutaneous) from 120 mg doses hampered patient compliance okhaotsfrq (ezqcytfzps ) View more | Positive | 01 Apr 2016 | ||
Phase 1 | 45 | hexxewbyta(vvgzlefnfx) = 80 mg once a day: no DLTs; 40 mg twice a day: five patients hqmzmqpxhf (nafmexjxmd ) View more | Positive | 01 Apr 2016 | |||
Phase 1 | - | gknrcyanue(lkufcytpmx) = ivwbsegyea ywhhszbwtz (bowvohjejh, 0.041) | Positive | 09 Jun 2015 | |||
Phase 1 | 36 | cwqzwirdvf(aojwzeulyp) = AUC-dose proportionality was observed elheapyrbn (wszzbbcrgq ) | - | 01 Oct 2014 | |||
Phase 1 | 141 | bwiiurjigt(mvnivvyyyg) = dcpwokynva tawbvjusvr (rcildwiyyr ) | - | 01 Oct 2014 |